Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MentiNova Inc.

Latest From MentiNova Inc.

Tech Transfer Roundup: Mustang, Nationwide Children’s Hospital Collaborate In Pediatric Glioblastoma

Partnership will test Mustang’s MB-101 with a second-generation oncolytic HSV-1 virus for potential in treating brain cancer. Canadian biotech launched by CCAB to fight the same cancer.

Companies Deals

MentiNova Inc.

For the past 50 years, levodopa, a dopamine precursor, has been the gold-standard treatment for people with Parkinson’s disease-, but there is a significant downside---a condition known as L-dopa-induced dyskinesia that emerges after using this medication for some time. MentiNova Inc., a clinical-stage, New Jersey-based biotechnology company, is repurposing the analgesic nalbuphine for the treatment of LID.


Parkinson’s Disease: Start-Ups Seek Breakthroughs And Money

Parkinson’s disease remains a significant undermet, attractive opportunity for drug developers, including early-stage biotechs. Profiles of MentiNova, Parkure and Prexton Therapeutics.


Start-Up Previews, September 2015

This Month's Profile Group, Parkinson’s Disease: Start-Ups Seek Breakthroughs And Money, features profiles of MentiNova, Parkure and Prexton Therapeutics. Plus these Start-Ups Across Health Care: Apifix, Monopar Therapeutics, MitoGenetics, Preora Diagnostics, and Viking Therapeutics.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals